Molecular biology plays an important role in the diagnosis and treatment of cancer. On a biological level, the development of cancer is characterized by the acquisition of genetic mutations which cause abnormal cell growth, eventually resulting in malignant disease. Understanding how molecular damage can cause these cancer-driving mutations can help design optimal treatment regimens
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Perhaps the greatest surprise of genetic studies of human disease is that 90% of top-scoring disease-associated loci lie outside protein-coding regions. This has increased the urgency of mapp...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
Technological advances in high throughput, low cost DNA sequencing coupled with the availability of a high quality reference assembly allow us to interrogate the genome with greater precision...
Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selectio...
Please click here to watch this webinar On DemandsiRNA-mediated silencing of gene expression has revolutionized the study of biology by enabling rapid and unbiased loss-of-function studies to...
Since the discovery and maturing of in vitro techniques that characterized neurotransmitter receptor systems in animal and human brain and subsequent development of in vitro and in vivo autor...
Every cell in the body can release several types of extracellular vesicles (EVs), often called ”exosomes” or ”microvesicles”. These vesicles carry a wide array of mole...
Date: Tuesday, February 10th, 2015Time: 12:00PM PST, 3:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
Date: Tuesday, February 10th, 2015Time: 9:00AM PST, 12:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
Soiled-bedding sentinels are not always efficient in detecting pathogens in rodent colonies. In this context, PCR-based testing can be more sensitive and is being advocated as adjunct to trad...
Dr. Oliver Kepp will be presenting on:Immunogenic cell death fingerprinting utilizing a high-throughput screening approachThe strategy of immunogenic cell death fingerprinting has been design...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
When the BCR/ABL1 fusion protein was identified in chronic myelogenous leukemia and the JAK2 V617F mutation was identified in patients with other myeloproliferative neoplasms (MPNs) such as p...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
The eukaryotic translation initiation factor eIF4E is an oncogene elevated in an estimated 30% of cancers. The traditional view is that eIF4E drives proliferation and survival by increasing t...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Perhaps the greatest surprise of genetic studies of human disease is that 90% of top-scoring disease-associated loci lie outside protein-coding regions. This has increased the urgency of mapp...
Biological datasets have become increasing large and complex. Knowledge databases and publicly available datasets are available for use in experimental planning and running results comparison...
Technological advances in high throughput, low cost DNA sequencing coupled with the availability of a high quality reference assembly allow us to interrogate the genome with greater precision...
Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selectio...
Please click here to watch this webinar On DemandsiRNA-mediated silencing of gene expression has revolutionized the study of biology by enabling rapid and unbiased loss-of-function studies to...
Since the discovery and maturing of in vitro techniques that characterized neurotransmitter receptor systems in animal and human brain and subsequent development of in vitro and in vivo autor...
Every cell in the body can release several types of extracellular vesicles (EVs), often called ”exosomes” or ”microvesicles”. These vesicles carry a wide array of mole...
Date: Tuesday, February 10th, 2015Time: 12:00PM PST, 3:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
Date: Tuesday, February 10th, 2015Time: 9:00AM PST, 12:00PM ESTFor the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology ...
Soiled-bedding sentinels are not always efficient in detecting pathogens in rodent colonies. In this context, PCR-based testing can be more sensitive and is being advocated as adjunct to trad...
Dr. Oliver Kepp will be presenting on:Immunogenic cell death fingerprinting utilizing a high-throughput screening approachThe strategy of immunogenic cell death fingerprinting has been design...
Mass spectrometry (MS)-based profiling of clinical specimens has been increasingly used in cancer research to characterize changes in protein expression between tumor and healthy tissue or be...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. N...
Both cell free DNA (cfDNA) and circulating tumor cells (CTC) represent important possible templates for mutation analysis of clinical samples. Each template has different theoretical advantag...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
When the BCR/ABL1 fusion protein was identified in chronic myelogenous leukemia and the JAK2 V617F mutation was identified in patients with other myeloproliferative neoplasms (MPNs) such as p...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
The eukaryotic translation initiation factor eIF4E is an oncogene elevated in an estimated 30% of cancers. The traditional view is that eIF4E drives proliferation and survival by increasing t...
Next-generation sequencing (NGS) has revolutionized extraction of genomic information, facilitating rapid advances in the fields of clinical research and molecular diagnostics. However, c...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
